Intra-laboratory study to determine the reproducibility of LLNA:BrdU-ELISA for the prediction of the skin sensitizing potential of chemicals

J Pharmacol Toxicol Methods. 2016 Nov-Dec:82:26-30. doi: 10.1016/j.vascn.2016.07.003. Epub 2016 Jul 22.

Abstract

Introduction: The Local Lymph Node Assay (LLNA) has been designated as the first-choice in vivo assay for identification the skin sensitization potential of new chemicals. The LLNA:BrdU-ELISA is a validated non-radioactive modification to the LLNA. An intra-laboratory reproducibility study for the LLNA:BrdU-ELISA was conducted to demonstrate its adequate performance in our laboratory.

Methods: Ten independent LLNA:BrdU-ELISAs with the preferred positive controls (PCs), i.e., 25% hexyl cinnamic aldehyde (HCA) and 25% eugenol, were conducted within a period of less than one year. In addition, different concentrations of 2,4-dinitrochlorobenzene (DNCB, an extreme sensitizer) (0.01, 0.1 and 0.3%), HCA (10, 25 and 50%) and eugenol (10, 25 and 50%), were tested to determine the EC1.6 values. Special Pathogen Free female CBA/J mice of 8-10weeks old were randomly allocated to the groups, each group having 4 mice. 25μl of AOO (vehicle, acetone: olive oil=4:1, v/v) or HCA, eugenol, DNCB at the needed concentration was applied to the dorsum of each ear of the mice, daily for 3 consecutive days. A single intraperitoneal injection of 0.5ml of BrdU solution (10mg/ml) was given on day 5. On day 6, a pair of auricular lymph nodes from each mouse was excised, and BrdU ELISA analysis was conducted.

Results: The result for each group is expressed as the mean Stimulation Index (SI). The mean of the 10 mean SIs for 25% HCA (2.58±0.95) and 25% eugenol (3.51±1.25) was not significantly different to that from the Interagency Coordinating Committee on the Validation of Alternative Methods (ICCVAM) (i.e., the data on the formal validation study for the LLNA:BrdU-ELISA by the ICCVAM) (3.03±2.00 for 25% HCA, 6.13±6.06 for 25% eugenol) (P>0.05), with even smaller Coefficient of Variations (CV) (36.8% for 25% HCA, 35.6% for 25% eugenol) than that from the ICCVAM (66.0% for 25% HCA, 98.8% for 25% eugenol). In addition, the EC1.6 values for HCA, eugenol and DNCB (15.2, 12.5 and 0.25%, respectively) were consistent with that from the ICCVAM (12.92, 8.85 and 0.34%, respectively).

Discussion: The results indicate that the reliability for our laboratory to conduct the LLNA:BrdU-ELISA is successfully determined.

Keywords: 2,4-Dinitrochlorobenzene (PubChem CID: 6); 5-Bromo-2-deoxyuridine (PubChem CID: 6035); Acetone (PubChem CID:180); Eugenol; Eugenol (PubChem CID: 3314); Hexyl cinnamic aldehyde; Hexyl cinnamic aldehyde (PubChem CID: 1,715,135); Local Lymph Node Assay:BrdU-ELISA; Methods; Reliability; Reproducibility; Skin sensitization.

MeSH terms

  • Acrolein / analogs & derivatives
  • Acrolein / pharmacology
  • Allergens / toxicity*
  • Animals
  • Bromodeoxyuridine / metabolism
  • Dermatitis, Allergic Contact* / diagnosis
  • Enzyme-Linked Immunosorbent Assay
  • Eugenol / pharmacology
  • Female
  • Laboratory Proficiency Testing / methods*
  • Local Lymph Node Assay*
  • Lymph Nodes* / cytology
  • Lymph Nodes* / immunology
  • Mice, Inbred CBA
  • Predictive Value of Tests
  • Reproducibility of Results
  • Sensitivity and Specificity

Substances

  • Allergens
  • hexyl cinnamic aldehyde
  • Eugenol
  • Acrolein
  • Bromodeoxyuridine